AstraZeneca takeover: In many ways, we are showing that this deal is not inevitable, says chief Pascal Soriot

The defiant AstraZeneca chief tells James Ashton that he has the right medicine to defeat Pfizer's takeover bid

However close Pfizer's bumper bid comes, Pascal Soriot's resolve appears not to be weakening. The Frenchman, who has found himself defending one of Britain's key industries over the last three weeks, still insists a £63bn takeover of the drug maker AstraZeneca is not a foregone conclusion.

"In many ways we are not just talking, we are actually showing," says Mr Soriot, his enthusiasm for a crop of late-stage research findings, including advances in psoriasis and lupus, shining through the tiredness wrought by a whirl of meetings with investors, scientists and ministers.

"From the view of giving proof that we are making progress with the pipeline, I must say I haven't had a week like this in a long time," he says, turning back to his desk after briefly admiring the afternoon sun.

It's true. Just as AstraZeneca argues it has a strong independent future, what a coincidence that the company's news flow has turned from a trickle to a gusher.

"At the end of the day, what it does is hopefully show people this deal is not inevitable," says Mr Soriot, 54. "A lot of people think this is a done deal and a question of price and we are actually very confident we can create shareholder value on our own."

After more investor visits yesterday, AstraZeneca's share price suggests the City is in two minds as to whether Viagra-maker Pfizer will succeed. Shares in both companies have eased since the offer was made, meaning the part-paper £50-a-share offer, rejected after a couple of hours' consideration a fortnight ago, is worth nearer £48 today.

Takeover Panel rules mean that the only shareholder Mr Soriot can speak up for is himself. Headlines about the £60m jackpot that directors stand to share if Pfizer wins out – around half of it due to him – clearly sting.

"A pretty substantial fraction of this money is actually made of shares that I bought myself," he says. "In fact, I borrowed money to buy those shares." Much of the rest, he says, is theoretical, from share options that have yet to vest.

You can believe it is the science not money that excites Mr Soriot, who began his career as a veterinary surgeon working with horses. He returns to the theme from Tuesday's Business Select Committee, when he warned that a tie-up could delay the development of life-saving medicines – a charge labelled a "red herring" by Pfizer's boss Ian Read.

Mr Read asserts that Pfizer would let the scientists decide which projects must be left well alone while the two companies are bashed together, but Mr Soriot is doubtful.

"These people don't like what happens if their lives are disrupted, if their work is disrupted. There is no amount of ring-fencing you can do to address that."

However, Mr Soriot knows he has a duty to consider an offer that could be in the best interests of shareholders, who Pfizer may appeal to directly over his head. He seems as concerned about how a deal would work, rather than just how much it would cost.

"The strategy the company would pursue has an impact on the execution of our plans. Is it a strategy where science and innovation have a big role? Any merger has to make savings but we still invest in research and development. Or is it a strategy where we focus on cashflow and cost savings, and science takes second priority?"

The Frenchman knows plenty about drugs mergers. At Roche, the Swiss group he quit to join AstraZeneca 17 months ago, he oversaw the integration of the US biotech firm Genentech. Mr Soriot also lived through the creation of Aventis, formed from Rhone-Poulenc and Hoechst. Amid such corporate gyrations, he has lived New Zealand, Japan, America and Switzerland, but regards Australia, where his grandchildren live, as home.

When he was recruited, AstraZeneca was struggling, having seen off his predecessor David Brennan in the shareholder spring. As big-selling ulcer treatment Nexium and antipsychotic drug Seroquel faced cheaper competition, the company was intent on shovelling cash out to shareholders rather than discovering the next great blockbuster.

He focused on restocking the drugs cabinet, with acquisitions of respiratory and cardio-vascular medicines, as well as buying Bristol-Myers Squibb out of a diabetes alliance.

However, Mr Soriot has not been immune to axe-wielding, cutting 11,000 jobs. The Frenchman's boldest move has been to commit to building a £330m state-of-the-art research centre in Cambridge while quitting an older plant in Cheshire.

Now money is set to take centre stage. Pfizer, which has been stalking the company since November, is expected to raise its offer early next week. It has until 26 May to launch a formal bid or walk away for six months. There will be little time for Mr Soriot, whose birthday is next Friday, to gaze out of the window.

News
people'It can last and it's terrifying'
News
people Emma Watson addresses celebrity nude photo leak
Arts and Entertainment
tv
News
Katie Hopkins appearing on 'This Morning' after she purposefully put on 4 stone.
peopleKatie Hopkins breaks down in tears over weight gain challenge
PROMOTED VIDEO
Life and Style
fashionModel of the moment shoots for first time with catwalk veteran
Life and Style
fashionAngelina Jolie's wedding dressed revealed
Sport
Alexis Sanchez, Radamel Falcao, Diego Costa and Mario Balotelli
footballRadamel Falcao and Diego Costa head record £835m influx
News
i100
Arts and Entertainment
Madame Vastra and Jenny Flint kiss in Doctor Who episode 'Deep Breath'
tv
Arts and Entertainment
Olivia Colman topped the list of the 30 most influential females in broadcasting
tv
Life and Style
techIf those brochure kitchens look a little too perfect to be true, well, that’s probably because they are
Arts and Entertainment
Danish director Lars von Trier
tvEnglish-language series with 'huge' international cast set for 2016
News
ebooksAn unforgettable anthology of contemporary reportage
Life and Style
tech
News
Kelly Brook
peopleA spokesperson said the support group was 'extremely disappointed'
Sport
Andy Murray celebrates a shot while playing Jo-Wilfried Tsonga
TennisWin sets up blockbuster US Open quarter-final against Djokovic
Arts and Entertainment
Hare’s a riddle: Kit Williams with the treasure linked to Masquerade
booksRiddling trilogy could net you $3m
Arts and Entertainment
Alex Kapranos of Franz Ferdinand performs live
music Pro-independence show to take place four days before vote
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

HR Generalist (standalone) - Tunbridge Wells - £32,000

£30000 - £32000 per annum: Ashdown Group: HR Generalist (standalone) - Tunbrid...

Derivatives Risk Commodities Business Analyst /Market Risk

£600 - £800 per day: Harrington Starr: Derivatives Risk Commodities Business A...

Power & Gas Business Analyst / Subject Matter Expert - Contract

£600 - £800 per day: Harrington Starr: Power & Gas Business Analyst/Subject Ma...

Infrastructure Lead, (Trading, VCE, Converged, Hyper V)

£600 - £900 per day: Harrington Starr: Infrastructure Lead, (Trading infrastru...

Day In a Page

'I’ll tell you what I would not serve - lamb and potatoes': US ambassador hits out at stodgy British food served at diplomatic dinners

'I’ll tell you what I would not serve - lamb and potatoes'

US ambassador hits out at stodgy British food
Radio Times female powerlist: A 'revolution' in TV gender roles

A 'revolution' in TV gender roles

Inside the Radio Times female powerlist
Endgame: James Frey's literary treasure hunt

James Frey's literary treasure hunt

Riddling trilogy could net you $3m
Fitbit: Because the tingle feels so good

Fitbit: Because the tingle feels so good

What David Sedaris learnt about the world from his fitness tracker
Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Second-holiest site in Islam attracts millions of pilgrims each year
Alexander Fury: The designer names to look for at fashion week this season

The big names to look for this fashion week

This week, designers begin to show their spring 2015 collections in New York
Will Self: 'I like Orwell's writing as much as the next talented mediocrity'

'I like Orwell's writing as much as the next talented mediocrity'

Will Self takes aim at Orwell's rules for writing plain English
Meet Afghanistan's middle-class paint-ballers

Meet Afghanistan's middle-class paint-ballers

Toy guns proving a popular diversion in a country flooded with the real thing
Al Pacino wows Venice

Al Pacino wows Venice

Ham among the brilliance as actor premieres two films at festival
Neil Lawson Baker interview: ‘I’ve gained so much from art. It’s only right to give something back’.

Neil Lawson Baker interview

‘I’ve gained so much from art. It’s only right to give something back’.
The other Mugabe who is lining up for the Zimbabwean presidency

The other Mugabe who is lining up for the Zimbabwean presidency

Wife of President Robert Mugabe appears to have her sights set on succeeding her husband
The model of a gadget launch: Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed

The model for a gadget launch

Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed
Alice Roberts: She's done pretty well, for a boffin without a beard

She's done pretty well, for a boffin without a beard

Alice Roberts talks about her new book on evolution - and why her early TV work drew flak from (mostly male) colleagues
Get well soon, Joan Rivers - an inspiration, whether she likes it or not

Get well soon, Joan Rivers

She is awful. But she's also wonderful, not in spite of but because of the fact she's forever saying appalling things, argues Ellen E Jones
Doctor Who Into the Dalek review: A classic sci-fi adventure with all the spectacle of a blockbuster

A fresh take on an old foe

Doctor Who Into the Dalek more than compensated for last week's nonsensical offering